# Ocular Therapeutix, Inc: overview

OCUL · Nasdaq · CIK 1393434 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ocul.md) · [Financials](/companies/ocul/financials.md) · [Filings](/companies/ocul/filings.md) · [Insiders](/companies/ocul/insiders.md)

Latest reported revenue: [$13.5m](/filings/0001104659-26-089450.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 3, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001104659-26-089450).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [15.4](/filings/0001104659-25-105919.md) | [17.1 d](/filings/0001104659-26-010664.md) | [10.7](/filings/0001104659-26-055256.md) | [13.5](/filings/0001104659-26-089450.md) | [14.5](/filings/0001104659-25-105919.md) | [13.3 d](/filings/0001104659-26-010664.md) | [10.8](/filings/0001104659-26-055256.md) | [13.5](/filings/0001104659-26-089450.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(298.2%)](/filings/0001104659-25-105919.md) | [(296.1%) d](/filings/0001104659-26-010664.md) | [(597.5%)](/filings/0001104659-26-055256.md) | [(502.6%)](/filings/0001104659-26-089450.md) | [(472.3%)](/filings/0001104659-25-105919.md) | [(526.5%) d](/filings/0001104659-26-010664.md) | [(865.5%)](/filings/0001104659-26-055256.md) | [(609.3%)](/filings/0001104659-26-089450.md) |
| Net margin | % | [(236.6%)](/filings/0001104659-25-105919.md) | [(283.3%) d](/filings/0001104659-26-010664.md) | [(598.7%)](/filings/0001104659-26-089450.md) | [(503.9%)](/filings/0001104659-26-089450.md) | [(477.3%)](/filings/0001104659-25-105919.md) | [(488.0%) d](/filings/0001104659-26-010664.md) | [(821.6%)](/filings/0001104659-26-089450.md) | [(584.5%)](/filings/0001104659-26-089450.md) |
| Diluted EPS | $ per share | [(0.22)](/filings/0001104659-25-105919.md) | not reported | [(0.38)](/filings/0001104659-26-055256.md) | [(0.39)](/filings/0001104659-26-089450.md) | [(0.38)](/filings/0001104659-25-105919.md) | not reported | [(0.40)](/filings/0001104659-26-055256.md) | [(0.35)](/filings/0001104659-26-089450.md) |
| Free cash flow | $m | [(36.6) d](/filings/0001104659-25-105919.md) | [(39.6) d](/filings/0001104659-26-010664.md) | [(46.6)](/filings/0001104659-26-055256.md) | [(56.5) d](/filings/0001104659-26-089450.md) | [(56.7) d](/filings/0001104659-25-105919.md) | [(57.1) d](/filings/0001104659-26-010664.md) | [(70.7)](/filings/0001104659-26-055256.md) | [(70.6) d](/filings/0001104659-26-089450.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [43.5](/filings/0001558370-24-002902.md) | [51.5](/filings/0001558370-25-002000.md) | [58.4](/filings/0001104659-26-010664.md) | [63.7](/filings/0001104659-26-010664.md) | [52.0](/filings/0001104659-26-010664.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(179.3%)](/filings/0001558370-24-002902.md) | [(152.7%)](/filings/0001558370-25-002000.md) | [(141.0%)](/filings/0001104659-26-010664.md) | [(269.6%)](/filings/0001104659-26-010664.md) | [(519.8%)](/filings/0001104659-26-010664.md) |
| Net margin | % | [(15.1%)](/filings/0001558370-24-002902.md) | [(138.0%)](/filings/0001558370-25-002000.md) | [(138.1%)](/filings/0001104659-26-010664.md) | [(303.7%)](/filings/0001104659-26-010664.md) | [(511.9%)](/filings/0001104659-26-010664.md) |
| Diluted EPS | $ per share | [(0.98)](/filings/0001558370-24-002902.md) | [(0.97)](/filings/0001558370-25-002000.md) | [(1.02)](/filings/0001104659-26-010664.md) | [(1.22)](/filings/0001104659-26-010664.md) | [(1.42)](/filings/0001104659-26-010664.md) |
| Free cash flow | $m | [(66.7)](/filings/0001558370-24-002902.md) | [(63.3)](/filings/0001558370-25-002000.md) | [(76.3)](/filings/0001104659-26-010664.md) | [(136)](/filings/0001104659-26-010664.md) | [(217)](/filings/0001104659-26-010664.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/ocul/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $322.5m | 32,844,043 |  | Added +190,279 |
| [Deep Track Capital, LP](/funds/1856083.md) | 2026-06-30 | $193.3m | 19,686,282 |  | Unchanged |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $190.3m | 19,376,555 |  | Added +3,243,624 |
| [Avoro Capital Advisors LLC](/funds/1633313.md) | 2026-06-30 | $123.1m | 12,540,000 |  | Added +225,000 |
| [Summer Road LLC](/funds/1604873.md) | 2026-06-30 | $119.9m | 12,208,296 |  | Added +328,471 |
| [Venrock Adviser, LLC](/funds/1615982.md) | 2026-06-30 | $101.6m | 10,346,926 |  | Unchanged |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $86.7m | 8,832,595 |  | Added +113,556 |
| [Logos Global Management LP](/funds/1792126.md) | 2026-06-30 | $52.0m | 5,300,000 |  | Added +1,450,000 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $51.4m | 5,233,282 |  | Added +524,863 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $49.3m | 5,021,092 |  | Added +491,907 |

## Recent filings

[All 852 filings](/companies/ocul/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-16 | 20:15 ET | [8-K](/filings/0001104659-26-116617.md) | 5.02 Departure or appointment of officers or directors | 0001104659-26-116617 |
| 2026-08-03 | 11:16 ET | [10-Q](/filings/0001104659-26-089450.md) | Quarterly report, period 2026-06-30 | 0001104659-26-089450 |
| 2026-08-03 | 11:07 ET | [8-K](/filings/0001104659-26-089443.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-089443 |
| 2026-06-12 | 20:23 ET | [8-K](/filings/0001104659-26-073496.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001104659-26-073496 |
| 2026-05-05 | 11:28 ET | [10-Q](/filings/0001104659-26-055256.md) | Quarterly report, period 2026-03-31 | 0001104659-26-055256 |
| 2026-05-05 | 11:06 ET | [8-K](/filings/0001104659-26-055241.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-055241 |
| 2026-04-30 | 21:17 ET | [DEF 14A](/filings/0001104659-26-053176.md) | Proxy statement, period 2026-06-11 | 0001104659-26-053176 |
| 2026-02-27 | 21:02 ET | [8-K](/filings/0001104659-26-021541.md) | 7.01 Regulation FD disclosure | 0001104659-26-021541 |
| 2026-02-05 | 12:58 ET | [10-K](/filings/0001104659-26-010664.md) | Annual report, period 2025-12-31 | 0001104659-26-010664 |
| 2026-02-05 | 12:13 ET | [8-K](/filings/0001104659-26-010633.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-010633 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-010664.md), filed Feb 5, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/a8b23c29-4789-4fba-a106-eaa2eb581425)

## About the filer

- CIK: 1393434
- Tickers: OCUL
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:38 ET. No prices; not investment advice.